Bavarian Nordic (BAVA.CO) announced a potential increase in its mpox vaccine production capacity, aiming to supply up to 13 million doses by the end of 2025. This is an upgrade from its earlier forecast of 10 million doses. The Danish biotech company is also exploring ways to expand capacity further, potentially adding up to 50 million more doses within the next 12-18 months, contingent upon regulatory approvals and market demand.
The company’s head of investor relations, Rolf Sass Sorensen, highlighted that the ability to ramp up production depends primarily on demand and favorable conditions. Bavarian Nordic is actively seeking collaborations and exploring advanced manufacturing techniques to meet the growing need for vaccines. Discussions are ongoing with partners in Africa and other regions to facilitate vaccine production and transfer.
The World Health Organization’s recent declaration of mpox as a global health emergency has intensified the urgency for vaccine availability. Bavarian Nordic’s efforts to increase production come in response to these heightened concerns. The Democratic Republic of Congo, currently at the center of the mpox outbreak, recently received its first batch of the vaccine.
Bavarian Nordic also revealed that some existing orders for mpox vaccines with the U.S. government will be rescheduled to 2025 to address other market requirements.
